11C-erlotinib brain uptake in Diffuse Intrinsic Pontine Glioma imaged by PET

11C-erlotinib brain uptake in Diffuse Intrinsic Pontine Glioma imaged by PET - 11C-erlotinib PET in DIPG

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47863

Enrollment

Registered

2018-02-28

Start date

2017-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brainstem glioma brainstem tumor

Interventions

IV infusion of 11C-erlotinib, once

DIPG

Erlotinib

Eligibility

Age

2 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Patients with MRI confirmed DIPG - Erlotinib use for at least 2 week - Age between 6 years and 19 years - Able to lay down quietly for 20 minutes

Exclusion criteria

Exclusion criteria: - Known hypersensitivity for erlotinib - Pregnancy - Clinically confirmed neurofibromatosis type I

Design outcomes

Primary

Measure	Time frame
Non-invasively determining the 11C-erlotinib brain and tumor uptake in DIPG patients by PET imaging.	—

Secondary

Measure	Time frame
Determining the EGFR expression in DIPG.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)